A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies-Reference-Cited by-同舟云学术

A drug–drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies

Published:2018-05-30 Issue:12 Volume:59 Page:2888-2895
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

de Jong Jan¹,Hellemans Peter²,De Wilde Severijn²,Patricia Daniel³,Masterson Tara³,Manikhas Georgii⁴,Myasnikov Alexander⁵,Osmanov Dzhelil⁶,Córdoba Raúl⁷,Panizo Carlos⁸,de Zwart Loeckie²,Snoeys Jan²,Chauhan Vijay⁹,Jiao James⁹,Sukbuntherng Juthamas¹⁰,Ouellet Daniele³

Affiliation:

1. Janssen Research & Development, San Diego, CA, USA;

2. Janssen Research & Development, Beerse, Belgium;

3. Janssen Research & Development, Spring House, PA, USA;

4. St. Petersburg City Oncology Hospital, St. Petersburg, Russian Federation;

5. Baranov Republican Hospital, Petrozavodsk, Russian Federation;

6. N.N. Blokhin Russian Academy of Medical Sciences, Moscow, Russian Federation;

7. START Madrid, University Hospital Fundacion Jimenez Diaz, Health Research Institute IIS-FJD, Madrid, Spain;

8. University Clinic of Navarra, Pamplona, Spain;

9. Janssen Research & Development, Raritan, NJ, USA;

10. Pharmacyclics LLC, Sunnyvale, CA, USA

Funder